NCT07793240
Circulating Tumor DNA (ctDNA) in High Grade Upper Tract Urothelial Cancer (UTUC)
At risk: Primary completion moved 2 months later.
See at-risk trials from Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Start date pushed from Oct 1, 2026 to Dec 1, 2026
- Eligibility criteria expanded, about 2 words
- Primary completion pushed from Oct 1, 2028 to Dec 1, 2028
- Study completion pushed from Oct 1, 2029 to Dec 1, 2029
- Notable Eligibility criteria expanded, about 27 wordsv2
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Arms and interventions
Patients HG UTUC planned for systemic therapy and or surgical intervention will be recruited and have sequential ctDNA ordered as per standard Signatera testing (approved for patients with high risk urothelial cancer undergoing immunotherapy or in perioperative setting) at or close to baseline, every 4-6 weeks on treatment, before and after surgical intervention, on surveillance and or adjuvant therapy.
Diagnostic tests: Signatera testing
Sites
1 site in 1 country
- Johns Hopkins University: Sidney Kimmel Comprehensive Cancer CenterBaltimore, Maryland, United States